Surmodics

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Surmodics reports Q1 growth, FDA hurdles, and strategic partnerships

Surmodics navigates FDA challenges with the SurVeil application while focusing on cost-saving measures and revenue growth strategies for fiscal 2023.
The company's strong technology foundation, partnership with Abbott, and customer acceptance of key products position it well for future growth.
Despite challenges in FDA approval and spending reductions, Surmodics remains committed to innovation, regulatory compliance, and strategic partnerships.
Opportunities in product commercialization, revenue growth, and asset preservation offer avenues for overcoming challenges and driving long-term success.

Surmodics reports solid Q2 growth, navigates FDA approvals and revenue challenges

Surmodics shows strong performance in medical device sales and strategic objectives execution.
Challenges include In Vitro Diagnostics revenue decline and revised fiscal guidance.
Opportunities lie in significant sales growth projections and regulatory milestones.
Financial stability maintained through cash utilization plan and spending reduction measures.
Overall, Surmodics navigates growth and challenges with a focus on FDA approvals and revenue growth.

Surmodics excels in Q3 with robust revenue growth and strategic partnerships

Surmodics delivered exceptional Q3 results, driven by strong revenue growth and operational achievements, setting the stage for continued success.
The company's focus on cash flow generation, disciplined expense management, and strategic partnerships with Abbott bode well for future growth and profitability.
While facing challenges such as COVID-related impacts and revenue sharing negotiations, Surmodics remains poised to capitalize on opportunities for growth and innovation.
With a solid financial position, expanded revenue guidance, and readiness to support Abbott's commercial initiatives, Surmodics is well-positioned for a promising future.

Surmodics reports robust Q4 earnings, eyes growth amidst challenges

Surmodics delivered strong financial performance in Q4 2023 and fiscal 2023, driven by revenue growth and operational improvements.
While facing challenges such as competitive dynamics and projected losses in fiscal 2024, the company is well-positioned to capitalize on opportunities.
Strategic achievements, product advancements, and financial stability position Surmodics for continued growth and market success in the coming year.
Emphasis on innovation, market expansion, and cost management will be crucial for Surmodics to navigate challenges and leverage growth opportunities.

Surmodics reports robust Q1 growth, eyes new product launches

Surmodics' Q1 2024 performance reflects strong revenue growth, operational efficiency, and successful product launches, positioning the company for continued success in the medical device and diagnostics markets.
While challenges such as incremental expenses and pricing dynamics exist, Surmodics' focus on innovation, financial discipline, and market responsiveness presents opportunities for sustained growth and competitive advantage.
With a strategic outlook towards driving revenue growth, expanding product offerings, and optimizing expenses, Surmodics aims to navigate challenges and capitalize on opportunities for long-term success and market leadership.

Surmodics reports robust Q2 growth, eyes profitability amid challenges

Surmodics' Q2 2024 performance reflects revenue growth, improved profitability, and product innovation, underpinned by strong R&D focus and strategic partnerships.
While facing challenges in achieving profitability and providing clear guidance for fiscal 2025, the company remains optimistic about growth opportunities and market expansion.
With a focus on enhancing margins, expanding product offerings, and leveraging partnerships, Surmodics is poised for continued growth and innovation in the medical device industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Surmodics' (SRDX) buyout of Vetex Medical adds second FDA 510 (k) cleared device to its thrombectomy platform.

Surmodics (SRDX) Boosts Portfolio With Vetex Medical Buyout

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Acquisition--Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical Limited

Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical Limited

National Vision Hlds

EYE vs. SRDX: Which Stock Is the Better Value Option?

EYE or SRDX: Which Is the Better Value Stock Right Now?

Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.

Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss

Surmodics, Inc.'s (SRDX) CEO Gary Maharaj on Q2 2021 Results - Earnings Call Transcript

SurModics (SRDX) delivered earnings and revenue surprises of 3.33% and -0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Beats Q2 Earnings Estimates

Shares of Surmodics (NASDAQ:SRDX) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share rose 1450.00% over the past year to $0.62, which missed the estimate of $0.63.

Recap: Surmodics Q2 Earnings

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #IVD--Surmodics Reports Second Quarter Fiscal 2021 Results and Issues Fiscal 2021 Revenue and EPS Guidance

Surmodics Reports Second Quarter Fiscal 2021 Results and Issues Fiscal 2021 Revenue and EPS Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics to Webcast Second Quarter Fiscal 2021 Earnings Conference Call on April 28.

Surmodics to Webcast Second Quarter Fiscal 2021 Earnings Conference Call on April 28

Phibro Animal Health

PAHC vs. SRDX: Which Stock Is the Better Value Option?

PAHC or SRDX: Which Is the Better Value Stock Right Now?

Hill-Rom Hlds

Owens & Minor

Let's take a look at the three MedTech stocks performing well lately, banking on a host of impressive developments.

Buy 3 MedTech Stocks That Are Outperforming S&P 500 in 2021

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Access--Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices

Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices

Investor optimism is high on Surmodics (SRDX) stock, courtesy of its solid prospects.

Why You Should Add Surmodics (SRDX) to Your Portfolio Now

Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q1 2021 Results - Earnings Call Transcript

SurModics (SRDX) delivered earnings and revenue surprises of 133.33% and -3.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

SurModics (SRDX) Beats Q1 Earnings Estimates

Shares of Surmodics (NASDAQ:SRDX) rose 2.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 60.00% over the past year to $0.02, which beat the estimate of ($0.09).

Recap: Surmodics Q1 Earnings

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Reports First Quarter Fiscal 2021 Results

Surmodics Reports First Quarter Fiscal 2021 Results

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #SRDX--Surmodics to Webcast First Quarter Fiscal 2021 Earnings Conference Call on February 9.

Surmodics to Webcast First Quarter Fiscal 2021 Earnings Conference Call on February 9

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #DCB--12-Month Data from Surmodics' TRANSCEND Trial Presented at LINC 2021. SurVeil™ Drug-Coated Balloon (DCB) demonstrates non-inferior safety and efficacy

12-Month Data from Surmodics' TRANSCEND Trial Presented at LINC 2021 Event

PAHC vs. SRDX: Which Stock Should Value Investors Buy Now?

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Surmodics--Surmodics Announces TRANSCEND Trial 12-Month Data to be Presented at LINC 2021 Virtual Event.

Surmodics Announces TRANSCEND Trial 12-Month Data to be Presented at LINC 2021 Virtual Event

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock?

Why Is SurModics (SRDX) Up 6.4% Since Last Earnings Report?

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Avess--Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020; Study finds 100 percent target lesion patency at 30 days.

6-Month Data From the Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020

ANI Pharma

Surgalign Holdings, Inc.

Vanda Pharmaceuticals

PetMed Express

According to the GuruFocus All-in-One Screener as of Nov. 5, the following medical technology stocks are popular among gurus.

News for Surmodics Stock (SRDX)